Author:
Almansi Amjad,Alqato Shahd,Bawardi Sami,Sabobeh Tariq,Al Madanat Heba,Alquadan Obadah,Al-Antary Eman
Abstract
Hemophagocytic lymphohistiocytosis (HLH) constitutes a rare and potentially life-threatening immunological syndrome. It manifests in both primary (genetic) and secondary (acquired) forms, exhibiting a diverse range of clinical and laboratory features, thereby posing challenges to accurate diagnosis, particularly within critical care settings. Early identification and intervention are of vital importance for improving patient survival. This article comprehensively explores the existing literature, encompassing the classification, pathophysiology, and clinical presentation of HLH. Special emphasis is placed on identifying prognostic factors, organ failure, and associated complications. Moreover, a detailed narrative of proposed management strategies, including immuno- and myelosuppressive options, is presented. Further research directions are suggested to enhance the understanding and treatment of this complex disorder.
Publisher
Jordanian American Physician Academy
Reference76 articles.
1. Janka G. Familial and acquired hemophagocytic lymphohistiocytosis. European Journal of Pediatrics [Internet; Dec 7;166(2):95–109. DOI: 10.1007/s00431-006-0258-1.
2. Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood 2011; 118: 4041.
3. Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood [Internet. DOI: 10.1182/blood-2015-01-551622.
4. Parikh SA, Kapoor P, Letendre L, et al. Prognostic Factors and Outcomes of Adults With Hemophagocytic Lymphohistiocytosis. Mayo Clinic Proceedings [Internet; Apr 1;89(4):484–92. DOI: 10.1016/j.mayocp.2013.12.012.
5. Henter JI, Elinder G, Öst Å. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. PubMed [Internet; Feb 1;18(1):29–33, https://pubmed.ncbi.nlm.nih.gov/1992521.